<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315327</url>
  </required_header>
  <id_info>
    <org_study_id>TSA Omega-3</org_study_id>
    <nct_id>NCT01315327</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Tourette's Disorder</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acids in Children and Adolescents With Tourette's Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tourette Association of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the safety and efficacy of omega-3 fatty acids (fish oil) for the
      treatment of Tourette's Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 20-week, double-blind, placebo (olive oil) controlled study examining supplemental
      fish oil in the treatment of tic and OCD symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Baseline and then weekly for 20 weeks</time_frame>
    <description>This assessment captures tic type and frequency as well as intensity and complexity, and impairment due to tics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)</measure>
    <time_frame>Baseline and then weekly for 20 weeks</time_frame>
    <description>Assesses type, frequency, and impairment of obsessions and compulsions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Tourette's Disorder</condition>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil placebo, looks and tastes identical to active intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Fatty Acids</intervention_name>
    <description>Omega-3 fatty acids (derived from fish oil)</description>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olive oil</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 6 through 18 inclusive

          -  Meet full DSM-IV diagnostic criteria for TD or chronic motor tic disorder

          -  Normal laboratory results, including serum chemistries, hematology, and urinalysis

          -  Must be able to swallow capsules.

          -  Must be of normal intelligence in the judgment of the investigator.

          -  Subjects and parents must possess an educational level, degree of understanding and
             command of the English language to enable them to communicate suitably with the
             investigator and study coordinator and to understand the nature of the study.

          -  Subjects and their legal representatives must be considered reliable.

        Exclusion Criteria:

          -  Organic brain disease, for example, traumatic brain injury residua

          -  Meeting criteria for mental retardation as defined by the DSM-IV.

          -  A history of seizure disorder (other than febrile seizure).

          -  A Subjects with history of Sydenham's Chorea.

          -  Autism, schizophrenia or other psychotic disorders.

          -  A primary diagnosis of a major mood disorder that requires ongoing psychiatric
             treatment.

          -  A neurological disorder other than a tic disorder.

          -  A documented auto-immune disorder.

          -  A major medical illness.

          -  A history of ongoing or previously undisclosed child abuse (risk of removal from home
             would not allow for consistent caretaker ratings).

          -  Subjects who, in the opinion of the investigator, are unsuitable in any other way to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vilma Gabbay, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J Coffey, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Child Study Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gabbay V, Babb JS, Klein RG, Panzer AM, Katz Y, Alonso CM, Petkova E, Wang J, Coffey BJ. A double-blind, placebo-controlled trial of Ï‰-3 fatty acids in Tourette's disorder. Pediatrics. 2012 Jun;129(6):e1493-500. doi: 10.1542/peds.2011-3384. Epub 2012 May 14.</citation>
    <PMID>22585765</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette's Disorder, Obsessive-Compulsive Disorder, tics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

